ライフサイエンスコーパス: personalized medicine

1 for either diagnosis or to guide treatment ("personalized medicine").

2 ug" (as is well understood in biology and in personalized medicine).

3 elated complications as we move towards more personalized medicine.

4 heir therapeutic potential for effective and personalized medicine.

5 may ultimately facilitate the development of personalized medicine.

6 dynamic treatment monitoring in this era of personalized medicine.

7 spects ranging from point-of-care devices to personalized medicine.

8 ional and implementation research that drive personalized medicine.

9 very problem in the area of human health and personalized medicine.

10 ividual tumors is a significant challenge in personalized medicine.

11 in predictive analytics and treatment toward personalized medicine.

12 ers, and advances drug screening, as well as personalized medicine.

13 tion of individual brains, a key feature for personalized medicine.

14 encourage the shift from population-based to personalized medicine.

15 l-based therapies an attractive strategy for personalized medicine.

16 populations, with immediate implications for personalized medicine.

17 rug resistance mechanisms for advancement of personalized medicine.

18 netic architecture and predictive aspects of personalized medicine.

19 atient-specific cells for drug discovery and personalized medicine.

20 ed drug delivery), opening new dimensions in personalized medicine.

21 cular systems biology, clinical research and personalized medicine.

22 thy human proteome baseline is essential for personalized medicine.

23 advantages in point-of-care diagnostics and personalized medicine.

24 py to further the clinical implementation of personalized medicine.

25 tanding of physiology and the development of personalized medicine.

26 ion plays an essential role in precision and personalized medicine.

27 ior to human trials, within the framework of personalized medicine.

28 aterial for clinical risk stratification and personalized medicine.

29 llenges privacy and data deidentification in personalized medicine.

30 nses in patients, thereby paving the way for personalized medicine.

31 gy technology, dentistry, drug delivery, and personalized medicine.

32 ct in tissue engineering, cancer therapy and personalized medicine.

33 ht us to the doorstep of widespread usage of personalized medicine.

34 e designed to facilitate cancer research and personalized medicine.

35 even more important from the perspective of personalized medicine.

36 adults because of the growing importance of personalized medicine.

37 es", holds promise for drastically improving personalized medicine.

38 and could be conducive to the development of personalized medicine.

39 applications within functional genomics and personalized medicine.

40 release has a pivotal role in the future of personalized medicine.

41 ic and will be a powerful tool in the era of personalized medicine.

42 (without pretreatment) in a single step for personalized medicine.

43 Biomarkers are rapidly gaining importance in personalized medicine.

44 om a one-size-fits-all approach to an era of personalized medicine.

45 paradigm, for the future of health care and personalized medicine.

46 , genes, and disease states, while advancing personalized medicine.

47 ponse, therefore paving the way towards more personalized medicine.

48 anisms of disease pathogenesis and promoting personalized medicine.

49 al for effective practical implementation of personalized medicine.

50 rating new hypotheses in cancer research and personalized medicine.

51 ion models as tools for drug development and personalized medicine.

52 y and dysregulated elements is now informing personalized medicine.

53 ay be utilized in both genomics research and personalized medicine.

54 ity, which presents an important step toward personalized medicine.

55 The zebrafish xenograft assay is ideal for personalized medicine.

56 olomics in the drug discovery process and in personalized medicine.

57 ease as we enter a new era of biomarkers and personalized medicine.

58 in biosensors as a result of the demand for personalized medicine.

59 ies in each child as a step toward achieving personalized medicine.

60 variation is a prerequisite for implementing personalized medicine.

61 typing, with transformative implications for personalized medicine.

62 n emerge as a powerful platform for enabling personalized medicine.

63 mismatched tissues and lack the advantage of personalized medicine.

64 ithin specific subgroups, guiding the way to personalized medicine.

65 ns, and so may be a viable option for future personalized medicine.

66 notypes to phenotypes for the development of personalized medicine.

67 tions for diagnostics and the development of personalized medicine.

68 selected features for various tasks such as personalized medicine.

69 ave myriad applications for regenerative and personalized medicine.

70 iologics can be tested and paves the way for personalized medicine.

71 plex diseases to make predictions useful for personalized medicine.

72 ch, and may provide critical information for personalized medicine.

73 turally important animals and crops, and for personalized medicine.

74 ce have a catalytic impact towards precision/personalized medicine.

75 responsiveness are also important aspects of personalized medicine.

76 l for understanding phenotypic diversity and personalized medicine.

77 ncer biology, with potential applications to personalized medicine.

78 including antibiotic or cancer treatment in personalized medicine.

79 major challenge to the evolving paradigm of personalized medicine.

80 rovide cost-effective mobile health care and personalized medicine.

81 ome important clinical tools in the field of personalized medicine.

82 ce, and is important in applied breeding and personalized medicine.

83 ated clinical tests and the growing field of personalized medicine.

84 cer drugs for clinical applications toward a personalized medicine.

85 ronmental monitoring, disease screening, and personalized medicine.

86 for the diagnosis of SNP-based diseases and personalized medicine.

87 l barriers to the wider potential success of personalized medicine.

88 esenting privileged tools for integrin-based personalized medicine.

89 eralized to other cancer types in the era of personalized medicine.

90 networks (from genomic sequences alone) for personalized medicine.

91 jor obstacle to effective cancer therapy and personalized medicine.

92 r new therapeutic targets and biomarkers for personalized medicine.

93 which is an unmet medical need in the era of personalized medicine.

94 ing of drug efficacy is highly desirable for personalized medicine.

95 tunities for early diagnosis of diseases and personalized medicine.

96 at the interface of chemistry, biology, and personalized medicine.

97 ing to the development of therapies based on personalized medicine.

98 s the synthesis of high-quality peptides for personalized medicine.

99 ogically coherent subgroups is important for personalized medicine.

100 toward a new generation of tissue models for personalized medicine.

101 cy at early stages of drug development or in personalized medicine.

102 y to the development of targeted therapy for personalized medicine.

103 nd the challenges for the imminent future of personalized medicine.

104 drug release with different applications in personalized medicine.

105 c systems biology, laying the foundation for personalized medicine.

106 rugs and therapeutic strategies, and promote personalized medicine.

107 endency, LHM may also be used in studies for personalized medicine.

108 g to continuous manufacturing processes, and personalized medicine.

109 applications in precision prevention and in personalized medicine.

110 dly becoming a highly promising strategy for personalized medicine.

111 ology and provide an alternative approach in personalized medicine.

112 sed, with an emphasis on their potential for personalized medicine.

113 a major bottleneck in targeting kinases for personalized medicine.

114 , thus constituting an important step toward personalized medicine.

115 nsensitive populations and form the basis of personalized medicine.

116 obiome might be used in drug development and personalized medicine.

117 f diseases and facilitate the development of personalized medicine.

118 ening, drug discovery, disease modeling, and personalized medicine.

119 tential for future point-of-care devices and personalized medicine.

120 g paths for the widespread implementation of personalized medicine.

121 ions, and the promise of breath analysis for personalized medicine.

122 drug developers and clinicians interested in personalized medicine.

123 broaden the application of proteogenomics in personalized medicine.

124 y of complex diseases and ultimately achieve personalized medicine.

125 pplication, providing additional avenues for personalized medicine.

126 ill pave the way towards the coveted goal of personalized medicine.

127 their potential application for research and personalized medicine.

128 is, and disease and might be used to develop personalized medicines.

129 plex genetic diseases and the development of personalized medicines.

130 Because we are now entering the era of personalized medicine, a systems biology approach mergin

131 omplexity of clinical research, a demand for personalized medicine, an increasing value of diversity,

132 ogies at diagnosis could open up avenues for personalized medicine and allow clinical resources to be

133 e the care of patients with AVD by promoting personalized medicine and early intervention.

134 that dynamic risk assessment will facilitate personalized medicine and enable innovative therapeutic

135 eir clinical translations for benefiting the personalized medicine and human health.

136 may help in the application of principles of personalized medicine and in decision making for targete

137 Changing demographics, the rise of personalized medicine and increased identification of bi

138 vel, which will be an important step towards personalized medicine and infectious disease management.

139 t microbial xenobiotic metabolism will guide personalized medicine and nutrition, inform toxicology r

140 on holds substantial potential for improving personalized medicine and patient outcomes.

141 ts reported in this work are significant for personalized medicine and point-of-care chemical treatme

142 elopment, help patient care planning through personalized medicine and support drug discovery program

143 medicine interventions as a key component of personalized medicine and tailored-made health care are

144 The role of personalized medicine and target treatment in the clinic

145 Personalized medicine and therapies represent the goal o

146 individual's brain is a crucial step toward personalized medicine and understanding the neural basis

147 PCa detection is critical to personalized medicine and varies considerably under an M

148 maceuticals across different patients (i.e., personalized medicine), and enabling cell-based therapie

149 drug resistance, combinatorial drug therapy, personalized medicine, and cancer metastasis are also re

150 e and raises the possibility of their use in personalized medicine applications.

151 rget interactions or phenotyping patients in personalized medicine applications.

152 and analyzing patient derived samples toward personalized medicine applications.

153 Here we have designed a personalized medicine approach called gene expression an

154 er Genome Atlas database indicated that this personalized medicine approach could also be applied to

155 nts offer predictions to be considered for a personalized medicine approach in treating pediatric UC.

156 ness of TSPO V(T) on symptom reduction, this personalized medicine approach of matching a marker of g

157 ved in AKU for a preventive, predictive, and personalized medicine approach to AKU.

158 These findings strongly support a personalized medicine approach to alcoholism treatment t

159 To help improve the personalized medicine approach to psychiatric care, we e

160 genotype-phenotype relations that support a personalized medicine approach to the diverse titinopath

161 r hormone replacement therapies as part of a personalized medicine approach to treating a variety of

162 Results support a personalized medicine approach to vitamin supplementatio

163 in drug efficacy linked to DNAJA1 suggests a personalized medicine approach where tumor DNAJA1 status

164 psilocybin and may therefore contribute to a personalized medicine approach within the potential fram

165 support these developments and facilitate a personalized medicine approach, PET imaging and quantifi

166 ormation arising from dynamic profiling in a personalized medicine approach.

167 the actual needs of each patient in a truly personalized medicine approach.

168 e management guidelines and development of a personalized medicine approach.

169 o have a large effect on systems biology and personalized medicine approaches that investigate the dy

170 lectric characterization are becoming viable personalized medicine approaches to treat a notoriously

171 including non-druggable targets facilitates personalized medicine approaches with less adverse effec

172 g on target selection, polypharmacology, and personalized medicine approaches, are discussed as a pat

173 vity provide a powerful framework to develop personalized medicine approaches, by helping to identify

174 hold special promise for the development of personalized medicine approaches.

175 t from a timely mechanistic insight enabling personalized medicine approaches.

176 a potential marker for patient profiling in personalized medicine approaches.

177 ng of liver cancer biology and in developing personalized-medicine approaches for the disease.

178 ants underlying disease risk and adoption of personalized medicine are currently limited by the chall

179 Ideas about personalized medicine are underpinned in part by evoluti

180 nt of the treatment strategy by implementing personalized medicine are warranted to achieve optimal d

181 ocesses for funding new medicines, including personalized medicines, are both robust and fit for purp

182 search with the potential of applications in personalized medicine as well as in drug development.

183 enotype data is important for preventive and personalized medicine as well as plant and animal breedi

184 ughput screening, cardiotoxicity testing and personalized medicine assays, and long-term (aspirationa

185 therapy and highlights the possible role for personalized medicine based on deiodinase polymorphisms.

186 tratified according to risk of IA, providing personalized medicine based on strategic evidence for th

187 drugs are emerging as promising avenues for personalized medicine because of the differential respon

188 Recent advances in personalized medicine, "big data", causal inference usin

189 valuation of Tdp2 status may be an important personalized medicine biomarker informing on individual

190 versity, enabling not just basic research in personalized medicine but also accurate diagnostics and

191 odels are becoming popular in the context of personalized medicine, but a new study shows that these

192 Molecular therapies are hallmarks of "personalized" medicine, but how tumors adapt to these ag

193 linical outcomes, has the potential to drive personalized medicine by enabling individualized risk st

194 fundamentally change clinical proteomics and personalized medicine by facilitating large-scale studie

195 pand the range of translational research and personalized medicine by identification of clinically-re

196 With the growing emphasis on personalized medicine, cell therapies hold great potenti

197 To achieve the mission of personalized medicine, centering on delivering the right

198 chniques in cell culture, microfluidics, and personalized medicine concomitantly improve, the potenti

199 moving forward toward future preventive and personalized medicine devices are also discussed.

200 oth the epithelial and stromal compartments, personalized medicine efforts to integrate molecular inf

201 re (1) criteria for specimen adequacy in the personalized medicine era, (2) team-based approaches to

202 Clinicians already face "personalized" medicine every day while experiencing the

203 The era of personalized medicine for advanced-stage non-small-cell

204 nt characteristics is a crucial step towards personalized medicine for Alzheimer's Disease.

205 specific drugs, creating the possibility of personalized medicine for autism spectrum disorders.

206 n starkly underrepresented in the pursuit of personalized medicine for brain illnesses.

207 icipated shift into a preventive paradigm of personalized medicine for breast cancer.

208 platform that has the potential to transform personalized medicine for cancer recurrence monitoring.

209 timately pave the way for the development of personalized medicine for cardiovascular diseases.

210 ange these circumstances and build access to personalized medicine for disadvantaged populations.

211 otype for different forms of CKD, supporting personalized medicine for individuals with kidney diseas

212 Robust developments of personalized medicine for next-generation healthcare hig

213 rker tests are critical to implementation of personalized medicine for patients at risk for or affect

214 therapeutic benefit to usher in a new era of personalized medicine for patients with ABCB4-dependent

215 blood sampling could facilitate delivery of personalized medicine for SCLC.

216 are globally and opened up new prospects for personalized medicine for the fetus.

217 logical disorders, and to the development of personalized medicines for them.

218 The focus of personalized medicine has been primarily genomic medicin

219 Personalized medicine has largely been enabled by the in

220 Over the past decade, personalized medicine has received considerable attentio

221 The concept of personalized medicine has recently emerged as a promisin

222 Personalized medicines hold promise for many diseases.

223 ne sequencing capability and a shift towards personalized medicine holds significant promise for p53

224 ing have enormous potential to revolutionize personalized medicine, however distinguishing disease-ca

225 h is important to consider when implementing personalized medicine in asthmatic patients.

226 necessity of considering the age effects for personalized medicine in cancers.

227 scale data and clinical data, and facilitate personalized medicine in cancers.

228 development of biomarker-based approaches to personalized medicine in cardiovascular disease has been

229 Here, we describe examples of personalized medicine in cardiovascular disease, discuss

230 to biological treatment and can be used for personalized medicine in Crohn's disease and autoimmune

231 ant parameters could provide a framework for personalized medicine in diabetes.

232 leveraging molecular endotypes to implement personalized medicine in EoE.

233 n genomic polymorphism data is important for personalized medicine in humans, plant and animal breedi

234 programs, and can aid in the development of personalized medicine in humans.

235 h EHRs to predict GDM, which will facilitate personalized medicine in maternal health management in t

236 nd that BTK-targeting SCOs have potential as personalized medicine in patients with XLA.

237 Personalized medicine in psychiatry provides the hope of

238 principle has acquired greater importance in personalized medicine in recent years, particularly in o

239 mice may lead to the implementation of truly personalized medicine in the clinic.

240 ead toward the application of stratified and personalized medicine in the rhinitis field.

241 outcome to treatment responses thus enabling personalized medicine in the selection of specific treat

242 Personalized medicine includes identifying patients most

243 enabled rapid identification of targets for personalized medicine, including cancer vaccines.

244 n recently because of their potential use in personalized medicine, including cancer-targeting treatm

245 otoxicity of tacrine, providing insights for personalized medicine initiatives.

246 search; interdisciplinary work suggests that personalized medicine is on the horizon.

247 It may be that if the goal of personalized medicine is to be realized and biomarkers a

248 nships, and the relative potential impact on personalized medicine, is the challenge of future resear

249 rstand the cancer resistance and move toward personalized medicine, it is essential to consider signa

250 These data may hold the promise of personalized medicine, leading to routinely available se

251 he Human Genome Project and subsequently the personalized medicine movement.

252 In the current era of personalized medicine, national and international regist

253 patient's immune system herald a new era of personalized medicine, offering hope for curative respon

254 Personalized medicine offers great potential benefits fo

255 d feasibility and patient enthusiasm for the personalized medicine paradigm, but have yet to demonstr

256 f genome-wide association studies (GWAS) and personalized medicine, predicting the impact of single n

257 Most physicians believe they practiced personalized medicine prior to the genomics era that fol

258 ogenomic data set to clinical application in personalized medicine programs is now the main challenge

259 Personalized medicine promises to advance and improve he

260 Personalized medicine provides a strategic approach to t

261 of TZD drugs, providing proof of concept for personalized medicine related to nuclear receptor genomi

262 The conventional approach to personalized medicine relies on molecular data analytics

263 Personalized medicines require understanding the molecul

264 Personalized medicine requires that treatments adapt to

265 Using the data from the Marshfield Personalized Medicine Research Project, a site in the el

266 al relevance as a platform for precision and personalized medicine research.

267 The success of personalized medicine rests on understanding the genetic

268 Novel medical approaches and personalized medicine seek to use genetic information to

269 ealth status and diseases states, and enable personalized medicine, sensitive and rapid detection of

270 We will argue that randomized trials of personalized medicines should be routinely supplemented

271 variants on mTOR activity levels and support personalized medicine strategies based on patient varian

272 y levels in clinical assessments and support personalized medicine strategies based on patient varian

273 d acquired resistance and the development of personalized medicine strategies for UTUC patients.

274 m cells (iPSCs) from human tissue for use in personalized medicine strategies or therapeutic testing

275 mework of brain IR in further development of personalized medicine strategies to effectively treat MD

276 Cs therefore have great potential for use in personalized medicine strategies.

277 pproach constitutes a potential strategy for personalized medicine that enhances inference from stati

278 As a challenge for personalized medicine, the C-allele, which has an overal

279 In an era of personalized medicine, the clinical community has become

280 y important therapeutic class, especially in personalized medicine, their development and optimizatio

281 nologies are essential to the realization of personalized medicine through continuously monitoring an

282 The realization of personalized medicine through human induced pluripotent

283 ore their importance for topics ranging from personalized medicine to theories of the evolution of ho

284 int, which will enable clinicians to deliver personalized medicine to TMD patients and eventually pro

285 peptides are a promising next generation of personalized medicines to reinstate biological harmony.

286 provide a framework for developing tools for personalized medicine toward the precise prediction, pre

287 in cell biology with future applications in personalized medicine, tumor identification as well as t

288 In the era of personalized medicine, until a more biologically based u

289 athophysiological functional tone and enable personalized medicine when a causative target-to-disease

290 chnique has significant utility in precision/personalized medicine, wherein this phenotypic screen ca

291 Realizing personalized medicine, which promises to enable early di

292 ifts, market changes, and patient demand for personalized medicine will require physicians to embrace

293 Advances in cancer research and personalized medicine will require significant new bridg

294 Success in designing clinical trials for personalized medicine will require the selection of pati

295 Effective implementation of personalized medicine will require tools to distinguish

296 The future of oncological treatment lies in personalized medicine with the combination of technologi

297 These findings offer a platform for personalized medicine with the concurrent discovery of f

298 ofiles, suggesting a possible way to realize personalized medicine with this noninvasive, fast, and a

299 can underpin metabotyping in the scenario of personalized medicine, with the aim of improving clinica

300 This novel machine-learning approach brings personalized medicine within reach, directly supporting